Glax­o­SmithK­line plumbs the dis­cov­ery field (again), bet­ting up to $815M for the lat­est add-on to its on­col­o­gy pipeline

Five years af­ter No­var­tis stepped up with a siz­able deal that gave them world­wide rights to Sur­face On­col­o­gy’s lead can­cer drug, Glax­o­SmithK­line is com­ing in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER